In one approach a scFv (single chain fragment variable) targeting carcino embryonie antigen (CEA) was joined to ULBP2 (UL16-binding protein 2) ligand; this fusion protein successfully activated and retargeted NK cells against tumor cell lines or primary patient tumor cells, and showed antitumor activity in both allogeneic and autologous settings [26, 31]. The gene discussed is ULBP2; the disease is neoplasm.